News

X‑Chem Announces Multi-Target Drug Discovery Collaboration with Taiho Pharmaceutical using DEX™ Technology

December 20, 2016

WALTHAM, Mass. – December 20, 2016 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics,…

News

X‑Chem and AbbVie Enter into Multi-Target Drug Discovery Partnership

July 26, 2016

WALTHAM, Mass. – July 26, 2016 - X-Chem, Inc., a privately held biotechnology company applying its cutting-edge lead discovery capabilities to the generation of novel small molecule therapeutics, today announced…

News

X‑Chem and Bayer Expand Drug Discovery Collaboration to Discover Novel Medicines

July 12, 2016

WALTHAM, Mass. – July 12, 2016 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics,…

News

X‑Chem Announces Achievement of Milestone in Alexion Collaboration

April 27, 2016

WALTHAM, Mass. – April 27 2016 – X-Chem, Inc. (X-Chem), a privately held biotechnology company utilizing its industry-leading DNA-Encoded X-Chem (DEX™) drug discovery platform for the identification of first-in-class small…

News

X‑Chem Announces License with Janssen for Protein:Protein Inhibitor Program in Inflammatory Disease

March 30, 2016

WALTHAM, Mass. – March 30, 2016 – X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative DNA-Encoded X-Chem (DEX™) drug discovery platform to generate novel therapeutics, today announced…

News

X‑Chem Collaborates with Sanofi on the Discovery of Lead Molecules against Multiple Challenging Targets

January 6, 2016

WALTHAM, Mass. – January 6 , 2015 - X-Chem, Inc., a privately held biotechnology company applying its cutting-edge lead discovery capabilities to the generation of novel small molecule therapeutics, announced…

News

X‑Chem and MD Anderson Cancer Center Enter Partnership to Discover Novel, Small Molecule Therapies for Cancer

January 6, 2016

WALTHAM, Mass. – January 6, 2016 –X-Chem, Inc., a privately held biotechnology company with a proprietary and innovative platform to generate small molecule therapeutics, today announced a multi-target agreement with…

News

X‑Chem Established as Independent, Privately Owned Biotechnology Company

January 6, 2016

WALTHAM, Mass. – January 6, 2016 –X-Chem announced today that it has been spun out to the shareholders of the parent company of Pharmaceutical Product Development, LLC (“PPD”) as an…